Transaction DateRecipientSharesTypePriceValue
Otonomy
Otonomy logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Otonomy, Inc. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Ménière's disease; OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand.


Ticker: OTIC
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1493566
Employees: 49
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $32 M (0%)
Assets, Current: $43 M (-32%)
Property, Plant and Equipment, Net: $3 M (0%)
Assets: $61 M (-26%)
Accounts Payable, Current: $665 Th (-42%)
Accrued Liabilities, Current: $5 M (0%)
Liabilities, Current: $11 M (-9%)
Long-term Debt, Excluding Current Maturities: $15 M (0%)
Liabilities: $41 M (-4%)
Common Stock, Value, Issued: $31 Th (0%)
Common Stock, Shares, Issued: $31 M (0%)
Additional Paid in Capital, Common Stock: $503 M (0%)
Retained Earnings (Accumulated Deficit): $483 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $17 Th (54%)
Stockholders' Equity (Parent): $20 M (0%)
Liabilities and Equity: $61 M (-26%)
Revenue: $10 Th (-94%)
Cost of Revenue: $511 Th (-29%)
Research and Development: $7 M (-52%)
Operating Income/Loss: $11 M (-50%)